BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang J, Frolov I, Russell SJ. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. J Gene Med 2004;6:1082-91. [PMID: 15368589 DOI: 10.1002/jgm.605] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Rius-Rocabert S, García-Romero N, García A, Ayuso-Sacido A, Nistal-Villan E. Oncolytic Virotherapy in Glioma Tumors.Int J Mol Sci. 2020;21. [PMID: 33066689 DOI: 10.3390/ijms21207604] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
2 Lee ES, Jin SY, Kang BK, Jung YT. Construction of replication-competent oncolytic retroviral vectors expressing R peptide-truncated 10A1 envelope glycoprotein. J Virol Methods 2019;268:32-6. [PMID: 30898575 DOI: 10.1016/j.jviromet.2019.03.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007;254:178-216. [PMID: 17383089 DOI: 10.1016/j.canlet.2007.02.002] [Cited by in Crossref: 208] [Cited by in F6Publishing: 180] [Article Influence: 13.9] [Reference Citation Analysis]
4 Estevez-Ordonez D, Chagoya G, Salehani A, Atchley TJ, Laskay NMB, Parr MS, Elsayed GA, Mahavadi AK, Rahm SP, Friedman GK, Markert JM. Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas. Neurosurg Clin N Am 2021;32:265-81. [PMID: 33781507 DOI: 10.1016/j.nec.2020.12.008] [Reference Citation Analysis]
5 Lin E, Salon C, Brambilla E, Lavillette D, Szecsi J, Cosset F, Coll J. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer. Cancer Gene Ther 2010;17:256-65. [DOI: 10.1038/cgt.2009.74] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
6 Kueberuwa G, Cawood R, Tedcastle A, Seymour LW. Tissue-Specific Attenuation of Oncolytic Sindbis Virus Without Compromised Genetic Stability. Human Gene Therapy Methods 2014;25:154-65. [DOI: 10.1089/hgtb.2013.202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
7 Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642-662. [PMID: 26323545 DOI: 10.1038/nrd4663] [Cited by in Crossref: 542] [Cited by in F6Publishing: 500] [Article Influence: 77.4] [Reference Citation Analysis]
8 Geiss BJ, Shimonkevitz LH, Sackal CI, Olson KE. Recombination-ready Sindbis replicon expression vectors for transgene expression. Virol J 2007;4:112. [PMID: 17963504 DOI: 10.1186/1743-422X-4-112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Trojan J, Cloix J, Ardourel M, Chatel M, Anthony D. Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 2007;145:795-811. [DOI: 10.1016/j.neuroscience.2007.01.021] [Cited by in Crossref: 82] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
10 Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. J Clin Invest 2019;129:1407-18. [PMID: 30829653 DOI: 10.1172/JCI122287] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 10.7] [Reference Citation Analysis]
11 Atkins GJ, Fleeton MN, Sheahan BJ. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008;10:e33. [PMID: 19000329 DOI: 10.1017/S1462399408000859] [Cited by in Crossref: 60] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
12 Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C. Alphavirus vectors for cancer therapy. Virus Res 2010;153:179-96. [PMID: 20692305 DOI: 10.1016/j.virusres.2010.07.027] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
13 Cai J, Yan G. The Identification and Development of a Novel Oncolytic Virus: Alphavirus M1. Hum Gene Ther 2021;32:138-49. [PMID: 33261513 DOI: 10.1089/hum.2020.271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene. 2005;24:7775-7791. [PMID: 16299537 DOI: 10.1038/sj.onc.1209044] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 4.8] [Reference Citation Analysis]
15 Ding L, Brown DM, Glass JI. Rescue of Infectious Sindbis Virus by Yeast Spheroplast-Mammalian Cell Fusion. Viruses 2021;13:603. [PMID: 33916100 DOI: 10.3390/v13040603] [Reference Citation Analysis]
16 Venticinque L, Meruelo D. Sindbis viral vector induced apoptosis requires translational inhibition and signaling through Mcl-1 and Bak. Mol Cancer 2010;9:37. [PMID: 20152035 DOI: 10.1186/1476-4598-9-37] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
17 Piver E, Collin C, Diatta A, Vaudin P, Pagès JC. Cellular factors influencing Semliki Forest Virus vector biology. Gene Ther 2005;12 Suppl 1:S111-7. [PMID: 16231043 DOI: 10.1038/sj.gt.3302625] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
18 Gray ER, Illingworth CJ, Coffin JM, Stoye JP. Binding of more than one Tva800 molecule is required for ASLV-A entry. Retrovirology 2011;8:96. [PMID: 22099981 DOI: 10.1186/1742-4690-8-96] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Monie DD, Bhandarkar AR, Parney IF, Correia C, Sarkaria JN, Vile RG, Li H. Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma. Neurosurg Focus 2021;50:E10. [PMID: 33524942 DOI: 10.3171/2020.12.FOCUS20855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhu B, Yang J, Fu X, Jiang Y. Anti-tumor Effects of Gene Therapy with GALV Membrane Fusion Glycoprotein in Lung Adenocarcinoma. Cell Biochem Biophys 2014;69:577-82. [DOI: 10.1007/s12013-014-9835-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
21 Kaminskyy V, Zhivotovsky B. To kill or be killed: how viruses interact with the cell death machinery. J Intern Med. 2010;267:473-482. [PMID: 20433575 DOI: 10.1111/j.1365-2796.2010.02222.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
22 Hardy RW, Rice CM. Requirements at the 3' end of the sindbis virus genome for efficient synthesis of minus-strand RNA. J Virol 2005;79:4630-9. [PMID: 15795249 DOI: 10.1128/JVI.79.8.4630-4639.2005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
23 Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbé J, Bonnotte B. Dendritic cell-tumor cell hybrids and immunotherapy: what's next? Cytotherapy 2011;13:774-85. [PMID: 21299362 DOI: 10.3109/14653249.2011.553593] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]